Key result
Ivabradine plus SoC adds ~$5,437 per QALY gained versus SoC alone in heart failure.
Why the study?
The cost-effectiveness of ivabradine added to standard of care in heart failure patients from the Iranian payer perspective was not established.
Is ivabradine plus standard of care cost-effective compared to standard of care alone in heart failure patients in Iran?
Is ivabradine plus standard of care cost-effective compared to standard of care alone in heart failure patients in Iran?
Ivabradine added to standard of care is a cost-effective treatment strategy for eligible heart failure patients in Iran.
May support ivabradine cost-effectiveness in Iranian HF; leaves open need for prospective validation before wider adoption.
OBJECTIVES: This study aimed to assess the cost-effectiveness of ivabradine plus standard of care (SoC) in comparison with current SoC alone from the Iranian payer perspective. METHODS: A cohort-based Markov model was developed to assess the incremental cost-effectiveness ratio (ICER) over a 10-year time horizon in a cohort of 1,000 patients. The baseline transition probabilities between New York Heart Association (NYHA), mortality rate, and hospitalization rate were extracted from the literature. The effect of ivabradine on mortality, hospitalization, and NYHA improvement or worsening were retrieved from the SHIFT study. The effectiveness was measured as quality-adjusted life-years (QALYs) using the utility values derived from Iranian Heart Failure Quality of Life study. Direct medical costs were obtained from hospital records and national tariffs. Deterministic and probabilistic sensitivity analyses were conducted to show the robustness of the model. RESULTS: Ivabradine therapy was associated with an incremental cost per QALY of USD $5,437 (incremental cost of USD $2,207 and QALYs gained 0.41) versus SoC. The probabilistic sensitivity analysis showed that ivabradine is expected to have a 60 percent chance of being cost-effective accepting a threshold of USD $6,550 per QALY. Furthermore, deterministic sensitivity analysis indicated that the model is sensitive to the ivabradine drug acquisition cost. CONCLUSIONS: The cost-effectiveness model suggested that the addition of ivabradine to SoC therapy was associated with improved clinical outcomes along with increased costs. The analysis indicates that the clinical benefit of ivabradine can be achieved at a reasonable cost in eligible heart failure patients with sinus rhythm and a baseline heart rate ≥ 75 beats per minute (bpm).
No takes yet. Share an insight, caveat, or question.
Taheri et al. (2018) studied Heart failure (n=1,000). Ivabradine plus standard of care vs. Standard of care alone was evaluated on Incremental cost-effectiveness ratio (ICER) / cost per QALY (USD $5,437 per QALY). Ivabradine plus standard of care was associated with an incremental cost of USD $5,437 per QALY gained versus standard of care alone in heart failure patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: